logo
U.S Neobank Slash Debuts Stablecoin with Stripe's Bridge for Global Business Payments

U.S Neobank Slash Debuts Stablecoin with Stripe's Bridge for Global Business Payments

Yahoo3 days ago
Slash, a San Francisco-based neobank for businesses, launched a payments and treasury platform powered by a new U.S. dollar stablecoin issued by Stripe's Bridge on Tuesday.
The product, called the Global USD Account, is aimed at companies seeking U.S. dollar access and cross-border payments without a U.S. bank account. It introduces Slash's own stablecoin, USDSL, which lets users store, send and receive dollars or stablecoins in one account, the company announced.
The setup aims to shorten settlement times and remove foreign exchange fees for cross-border payments to U.S. suppliers, the company said in an interview with CoinDesk.
Stablecoins, a type of cryptocurrencies pegged to external assets like the U.S. dollar, have grown into a $250 billion market, often touted as a faster, cheaper option for international payments. Interest in the sector has accelerated since U.S. President Donald Trump signed the GENIUS Act into law, setting new federal standards for stablecoin issuers.
Global banks and retailers including Amazon and Walmart are reportedly exploring stablecoin products, and payments firms like PayPal and Stripe have made significant moves in the space. Stripe acquired stablecoin infrastructure firm Bridge last year for $1.1 billion.
Slash's first foray into stablecoins allowed customers to send and receive USDC (USDC) and USDT (USDT) payments on the platform without having to hold the tokens, converting them automatically to U.S. dollars.
"It's super interesting because we were very much not a crypto company," Cardenas said, adding that he personally didn't know much about blockchain technology. "But then we had these wholesalers and marketing agencies telling us we need to have stablecoin payments to accept money from customers at lower cost."
"So we shipped it for them," he said.
Launched in December, that feature now already processes nearly $1 billion annualized volume and inspired the firm to go bigger with stablecoins, Cardenas said.
The firm now targets crypto companies that want to consolidate their treasury management that previously needed separate accounts at traditional banks, exchanges and custody providers. With the new slate of products, clients can convert between stablecoins, manage balances and off-ramp to U.S. bank accounts through ACH, wire or SWIFT transfers. They can also earn yield on their balances without triggering securities rules, the company said.
Future plans include launching a card that lets businesses spend their stablecoin balances and potentially a wallet for holding other crypto assets, Cardenas said.
In May, Slash raised $41 million in a Series B round led by Goodwater Capital, valuing the company at $370 million.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Calumet Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Calumet Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Yahoo

time2 minutes ago

  • Yahoo

Calumet Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Explore Calumet's Fair Values from the Community and select yours Calumet (NASDAQ:CLMT) Second Quarter 2025 Results Key Financial Results Revenue: US$1.03b (down 9.4% from 2Q 2024). Net loss: US$147.9m (loss widened by 271% from 2Q 2024). US$1.70 loss per share (further deteriorated from US$0.49 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Calumet Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 8.3%. Earnings per share (EPS) missed analyst estimates significantly. Looking ahead, revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Oil and Gas industry in the US. Performance of the American Oil and Gas industry. The company's shares are down 7.4% from a week ago. Risk Analysis We should say that we've discovered 3 warning signs for Calumet (2 don't sit too well with us!) that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio

Emera Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Emera Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Yahoo

time2 minutes ago

  • Yahoo

Emera Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Explore Emera's Fair Values from the Community and select yours Emera (TSE:EMA) Second Quarter 2025 Results Key Financial Results Revenue: CA$1.99b (up 23% from 2Q 2024). Net income: CA$154.0m (up 19% from 2Q 2024). Profit margin: 7.7% (down from 8.0% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: CA$0.52 (up from CA$0.45 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Emera Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 9.7%. Earnings per share (EPS) missed analyst estimates by 30%. Looking ahead, revenue is forecast to grow 1.4% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Electric Utilities industry in North America. Performance of the market in Canada. The company's shares are up 3.7% from a week ago. Risk Analysis Before you take the next step you should know about the 2 warning signs for Emera that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Spectral Medical Second Quarter 2025 Earnings: CA$0.007 loss per share (vs CA$0.016 loss in 2Q 2024)
Spectral Medical Second Quarter 2025 Earnings: CA$0.007 loss per share (vs CA$0.016 loss in 2Q 2024)

Yahoo

time2 minutes ago

  • Yahoo

Spectral Medical Second Quarter 2025 Earnings: CA$0.007 loss per share (vs CA$0.016 loss in 2Q 2024)

Explore Spectral Medical's Fair Values from the Community and select yours Spectral Medical (TSE:EDT) Second Quarter 2025 Results Key Financial Results Revenue: CA$813.0k (up 73% from 2Q 2024). Net loss: CA$1.93m (loss narrowed by 56% from 2Q 2024). CA$0.007 loss per share (improved from CA$0.016 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Spectral Medical Earnings Insights Looking ahead, revenue is forecast to grow 72% p.a. on average during the next 3 years, compared to a 66% growth forecast for the Biotechs industry in Canada. Performance of the Canadian Biotechs industry. The company's shares are down 1.2% from a week ago. Risk Analysis Be aware that Spectral Medical is showing 4 warning signs in our investment analysis and 3 of those are significant... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store